203 related articles for article (PubMed ID: 34916576)
1. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
[TBL] [Abstract][Full Text] [Related]
2. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
4. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
[TBL] [Abstract][Full Text] [Related]
5. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
6. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
7. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
8. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
Manousaridis K; Peter-Reichart S; Mennel S
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
[TBL] [Abstract][Full Text] [Related]
9. Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study.
Paul C; Heun C; Müller HH; Hoerauf H; Feltgen N; Wachtlin J; Kaymak H; Mennel S; Koss MJ; Fauser S; Maier MM; Schumann RG; Mueller S; Chang P; Schmitz-Valckenberg S; Kazerounian S; Szurman P; Lommatzsch A; Bertelmann T
Br J Ophthalmol; 2018 Aug; 102(8):1092-1097. PubMed ID: 29089354
[TBL] [Abstract][Full Text] [Related]
10. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
[TBL] [Abstract][Full Text] [Related]
11. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
[No Abstract] [Full Text] [Related]
12. The Portuguese Experience with Ocriplasmin in Clinical Practice.
Figueira J; Martins D; Pessoa B; Ferreira N; Meireles A; Sampaio A; Carneiro Â; Vaz F; Nascimento J; Moreno N; Roque J; Domingues M; Flores R; Teixeira C; Conde E; Henriques F; Proença H; Pita Negrão J; Barbosa M; Silva R; Vaz-Pereira S; Pereira Neves P; Gomes N; Raimundo M;
Ophthalmic Res; 2016; 56(4):186-192. PubMed ID: 27438077
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
14. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
[TBL] [Abstract][Full Text] [Related]
15. Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.
Paul C; Müller HH; Raber T; Bertelmann T;
PLoS One; 2022; 17(7):e0270120. PubMed ID: 35877658
[TBL] [Abstract][Full Text] [Related]
16. Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH.
Chan CK; Mein CE; Glassman AR; Beaulieu WT; Calhoun CT; Jaffe GJ; Jampol LM; MacCumber MW; Maguire MG; Maturi RK; Salehi-Had H; Rofagha S; Sun JK; Martin DF;
Ophthalmology; 2021 Nov; 128(11):1592-1603. PubMed ID: 33989683
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance.
Muqit MMK; Hamilton R; Ho J; Tucker S; Buck H
PLoS One; 2018; 13(5):e0197072. PubMed ID: 29768451
[TBL] [Abstract][Full Text] [Related]
18. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of ocriplasmin for patients with vitreous macular traction.
Zhang WF; Zhao XY; Meng LH; Wang DY; Feng S; Chen YX
Acta Ophthalmol; 2022 Feb; 100(1):e304-e313. PubMed ID: 34021702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
